^
Association details:
| Biomarker: | ALK rearrangement |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Avastin (bevacizumab) (VEGF-A inhibitor) + Alecensa (alectinib) (ALK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Alectinib in Combination With Bevacizumab in ALK Positive NSCLC
Excerpt:
...Subjects with NSCLC with known ALK-rearrangement tested with FDA-approved test (IHQ or FISH)....
Trial ID:
Source:
Title:
Phase I/II Trial of Alectinib and Bevacizumab in Patients With Advanced, Anaplastic Lymphoma Kinase (ALK)-Positive, Non-Small Cell Lung Cancer
Excerpt:
...- Molecular confirmation of an ALK rearrangement....
Trial ID:
Less C2 evidence
Source:
Title:
Updated Survival Data in Advanced ALK-rearranged Non-small Cell Lung Cancer Treated with Alectinib and Bevacizumab in the ALEK-B Study
Published date:
08/08/2023
Excerpt:
ALEK-B is an open-label phase II trial investigating the efficacy and safety of alectinib (600mg BID) and bevacizumab (15mg/kg) combination every three weeks in treatment naïve patients with advanced ALK fusion-positive NSCLC. All patients had molecular confirmation of ALK rearrangement in tissue by Next-generation sequencing (Foundation One CDx) at baseline and at disease progression....Alectinib and bevacizumab combination was confirmed to be safe and highly effective with a longer follow-up.
Trial ID:
Source:
Title:
Safety and activity of alectinib plus bevacizumab in patients with advanced ALK-rearranged non-small-cell lung cancer: a phase I/II study
Published date:
12/09/2021
Excerpt:
Here, we carried out a phase I/II trial to evaluate the safety and efficacy of bevacizumab plus alectinib in patients with advanced ALK-rearranged NSCLC….Overall, nine patients (81.8%) had confirmed objective responses, of which one (9.1%) was a complete response (Figure 1A). All had disease control (DCR 100%). The median PFS of the overall population was 19.1 months (95% CI 4.3 months-not reached) after a median follow-up of 34.9 months (median follow-up for patients still alive by the end of the study: 37 months) (Figure 2A).
DOI:
https://doi.org/10.1016/j.esmoop.2021.100342
Trial ID:
